PI3Kδ and primary immunodeficiencies. by Lucas, Carrie L et al.
PI3Kδ and primary immunodeficiencies
Carrie L. Lucas1,2, Anita Chandra3,4, Sergey Nejentsev4, Alison M. Condliffe5, and Klaus 
Okkenhaug3
1Molecular Development of the Immune System Section, Laboratory of Immunology, and Clinical 
Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of 
Health, Bethesda, Maryland, USA
3Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge CB22 
3AT, UK
4Department of Medicine, University of Cambridge, CB2 0QQ, UK
5Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, S10 2RX, 
UK
Abstract
Primary immunodeficiencies are inherited disorders of the immune system, often caused by the 
mutation of genes required for lymphocyte development and activation. Recently, several studies 
have identified gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD 
(which encodes p110δ) and PIK3R1 (which encodes p85α) that cause a combined 
immunodeficiency syndrome, referred to as activated PI3Kδ syndrome (APDS) or p110δ-
activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (PASLI). 
Paradoxically, both loss-of-function and gain-of-function mutations that affect these genes lead to 
immunosuppression, albeit via different mechanisms. Here, we review the roles of PI3Kδ in 
adaptive immunity, describe the clinical manifestations and mechanisms of disease in APDS and 
highlight new insights into PI3Kδ gleaned from these patients, as well as implications of these 
findings for clinical therapy.
Introduction
Activated PI3Kδ syndrome (APDS; also known as PASLI) is among a growing number of 
newly defined primary immunodeficiency (PID) syndromes in which the causal mutations 
have been identified by next-generation sequencing. The clinical manifestations of APDS 
are diverse and heterogeneous (Box 1), but the majority of patients present with recurrent 
respiratory infections, often associated with airway scarring (bronchiectasis) and ear and 
sinus damage, which is suggestive of antibody (B cell) deficiency. Severe, recurrent or 
persistent infections with herpes family viruses, indicating defective T cell function, are also 
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common in this condition, and may cause early death in some affected individuals. Many 
patients develop benign lymphadenopathy, often associated with hepatosplenomegaly, and 
there is a substantially increased risk of B cell lymphoma associated with APDS (Box 1). 
Increased susceptibility to viral infection and poor recall responses of memory T cells 
differentiate APDS from isolated hypogammaglobulinemia 1–4, hence APDS should be 
considered a combined immunodeficiency5. More than 100 patients have been reported to 
date with APDS, but the precise incidence is not yet known6, 7.
APDS is caused by heterozygous gain-of-function (GOF) mutations in PIK3CD or PIK3R1 
that induce hyperactivation of the protein products p110δ or p85α, respectively1–4. The 
p85α regulatory subunit and p110δ catalytic subunit together form the heterodimeric lipid 
kinase PI3Kδ, which is engaged by multiple receptors in cells of the immune system, 
including the B cell receptor (BCR) and the T cell receptor (TCR), as well as cytokine and 
costimulatory receptors. Homozygous loss-of-function (LOF) mutations in these same 
subunits cause a distinct and much rarer form of immunodeficiency in humans, which can be 
re-capitulated in mice8–10, and this apparent dichotomy, together with the clinical features 
of the affected patient groups, has informed our understanding of the role of PI3Kδ in 
immune cell development and function.
In this review, we will summarise what is known about PI3Kδ, focusing on its regulation of 
adaptive immune responses. Much of this knowledge derives from studies using gene-
targeted mice. We will then summarise the two cases that have been reported on PI3Kδ-
deficiency in humans, before describing in greater detail the clinical and immunological 
manifestations of APDS.
Overview of class I PI3Ks
The class IA PI3Ks are heterodimeric proteins composed of (and named after) a p110α, 
p110β or p110δ catalytic subunit that constitutively associates with a p85 regulatory subunit; 
the sole class IB PI3K is composed of the p110γ catalytic subunit that interacts with a p101 
or p84 regulatory subunit (Table 1). p110α and p110β are broadly expressed, whereas 
p110γ and p110δ are predominantly expressed by leukocytes. Although there is substantial 
potential for redundancy among the catalytic subunits, unique roles for each individual p110 
isoform have been described, reflecting their different expression patterns as well as how 
they are engaged by their respective receptors8, 11. For example, p110α is activated by 
insulin-like receptors and regulates growth, metabolism and angiogenesis11, whereas p110β 
contributes to metabolic signalling and has been shown to regulate responses of mouse 
neutrophils to immune complexes 12, 13. P110γ is highly expressed in myeloid cells and 
contributes to chemotactic responses, as well as reactive oxygen species (ROS) production in 
neutrophils14. Together with p110δ, p110γ is also important during pre-T cell development 
in the thymus15. p110δ, which is the focus of this review, is highly expressed both in 
lymphocytes and myeloid cells and is activated by antigen receptors, costimulatory 
receptors, cytokine receptors and growth factor receptors8.
Class I PI3Ks catalyse the phosphorylation of PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3 
(PIP3), which acts as a membrane tether for cell signalling proteins with pleckstrin 
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homology (PH) domains. Prominent among these are PDK1 and AKT, which act in concert 
to phosphorylate substrates such as the FOXO transcription factors (which become 
inactivated) and regulators of the mTOR complex 1 (which becomes activated). Therefore, 
activation of class I PI3Ks results in inactivation of FOXO transcription factors. In 
lymphocytes, BTK and ITK are PIP3-responsive tyrosine kinases that contribute to the 
activation of phospholipase C-gamma (PLCγ) and other downstream signalling proteins 
(Figs 1, 2). The lipid phosphatase PTEN converts PIP3 back to PtdIns(4,5)P2 8.
Class IA PI3K regulatory subunits are encoded by three different genes (PIK3R1, PIK3R2 
and PIK3R3) (Table 1). PIK3R1 encodes p85α, p55α and p50α (each from an alternative 
transcription start site), PIK3R2 encodes p85β, and PIK3R3 encodes p55γ 16. These 
regulatory subunits have SH2 domains, which bind phosphorylated YXXM motifs of cell 
surface receptors and membrane-associated proteins. p85α, p55α, p50α and p85β are 
ubiquitously expressed, whereas p55γ is mainly expressed in the brain and testes 16. Any of 
the class IA PI3K regulatory subunits can bind to p110α, p110β and p110δ without apparent 
selectivity. PI3Kδ is best understood to comprise p85α with p110δ, but association between 
p110δ and any of the other class IA PI3K regulatory subunits is also possible. It is also 
important to recognise that p85α has many p110δ-independent functions, as it can also bind 
p110α and p110β 16.
The class IA PI3K regulatory subunits influence the p110 catalytic subunits in three ways17: 
they prevent proteolytic degradation of p110; they inhibit p110 catalytic activity; and they 
recruit the p110 subunit to tyrosine phosphorylated proteins at the plasma membrane.
Once the SH2 domains of p85α are engaged by phosphotyrosines, the inhibitory contacts 
with p110 are relieved17. Thus, mutations in the PIK3R1 gene can influence PI3K activity 
by allowing the degradation of p110δ or by diminishing its recruitment to receptors (in the 
case of PIK3R1 null or LOF mutations), or by releasing the inhibitory action of p85α on 
p110δ (in the case of PIK3R1 GOF mutations). In addition to the regulatory subunits, 
p110α and p110δ can bind RAS and p110β binds RAC or CDC42. These small GTPases 
help tether the p110 subunit to the membrane once it has been recruited to a receptor via its 
regulatory subunit17, 18.
PI3Kδ and immunity: lessons from mice
Prior to the description of APDS, most of our knowledge of the role of PI3Kδ in immunity 
and infection was based on genetic and pharmacological studies using mouse models. The 
GOF mutations that cause APDS have recently been shown to result in increased basal and 
stimulated PIP3 levels and PIP3-dependent signalling cascades in patient-derived 
lymphocytes1–4, and the study of these patients may give us new insights into how the 
balance of PI3Kδ activity regulates immune cell functions. Here, we summarise what these 
studies in mice have taught us, before describing the immunological phenotypes of human 
patients with mutations in PIK3R1 or PIK3CD.
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Loss of PI3Kδ function in mouse B cells
In mice, early B cell development in the bone marrow is only mildly affected by the loss of 
p85α or p110δ19–23, whereas the combined loss of p110α and p110δ leads to a near-
complete development block at the pro-B cell stage24. However, mice lacking the p85α or 
p110δ subunits have fewer follicular B cells, lack marginal zone (MZ) B cells and peritoneal 
B1 B cells, have reduced serum immunoglobulins, and respond poorly to vaccination19–23. 
PI3Kδ couples BCR activation with both PIP3 production and signalling events downstream 
of the BCR (Fig 1). PI3Kδ-deficient B cells fail to respond to mitogenic stimuli, but undergo 
class-switch recombination (CSR) in response to interleukin-4 (IL-4) and lipopolysaccharide 
(LPS) in vitro19–26. However, mice lacking p110δ selectively in B cells can produce high-
affinity IgG antibodies in response to immunisation with the T cell-dependent (TD) antigen 
NP-CGG27 (but as discussed later, germline loss of PIK3R1 or PIK3CD leads to attenuated 
TD antibody responses). By contrast, PI3Kδ activity within B cells is required for T cell-
independent (TI) antibody responses . This may be due in part to the loss of B1 and MZ B 
cell subsets, which are the dominant B cell subsets that respond to TI antigens, in PI3Kδ-
deficient mice21, 22, 27, 28.
Consequences of hyperactive PI3Kδ signalling in B cells in mice
While there are several mouse models of LOF mutations in Pik3cd, the phenotype of Pik3cd 
GOF-mutant mice remains to be described. We can however, make inferences from other 
models of hyperactive PI3K signalling (in which Pten or Foxo1 is ablated in the germline or 
in B cells) or from mice expressing a membrane-bound form of p110α in B cells. PTEN 
antagonises PI3K signalling and hence its ablation leads to elevated PIP3 levels. FOXO 
transcription factors are negatively regulated by PI3K-AKT, and hence, their loss mimics 
some of the effects of hyperactive PI3K-AKT signalling. FOXO transcription factors induce 
the expression of genes involved in immunoglobulin gene recombination and development 
such as Rag1, Rag2, Ikaros and Il7a (Fig 1)29–31. Failure to undergo VDJ recombination 
because of elevated PI3K signalling and subsequent inactivation of FOXO1 can lead to a 
partial block of B cell development in the bone marrow29, 30. In addition, elevated PI3K 
signalling can increase the sensitivity of developing Pten-null B cells to negative selection 
by self antigens32. Interference with RAG expression and/or negative selection may lead to 
the development of B cells with aberrant phenotypes, as observed in patients with APDS 
(see later).
Activation-induced cytidine deaminase (AID; encoded by Aicda) is the master regulator of 
CSR and somatic hypermutation (SHM) 33. Deletion of Pten or Foxo1 in B cells impairs 
immunoglobulin class switching26, 30, 34, 35, suggesting that increased PI3K signalling in 
B cells antagonise this process. Indeed, addition of a PI3Kδ inhibitor can restore CSR in 
Pten-/- cells in vitro 35. AID is induced by FOXO1 and in-vitro activated Foxo1–/– B cells 
(which mimic B cells with GOF PI3Kδ mutations) exhibit impaired CSR, due partially to 
the loss of Aicda transcription; however, inefficient CSR was still observed in Pten–/– B cells 
in the presence of ectopic AID, suggesting that PI3K signalling also regulates CSR by 
affecting AID function at the post-transcriptional level26, 34, 35. During the germinal centre 
reaction , B cells cycle between the light zone and dark zone. B cells interact with cognate T 
cells in the light zone, and if they receive the appropriate signals, undergo CSR and then 
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traffic to the dark zone where they proliferate and undergo SHM36. When, Foxo1 was 
deleted specifically in germinal centre B cells, CSR was impaired despite normal Aicda 
transcription and AID protein expression. This suggests that FOXO1 regulates the targeting 
of AID to the immunoglobulin gene locus, that FOXO1 targets other genetic loci required 
for CSR and SHM, and/or that Foxo1 deletion in germinal centre B cells affects the 
expression of other proteins required for CSR37, 38. Moreover, Foxo1 ablation or induction 
of PI3K activity in germinal centre B cells led to loss of germinal centre dark zones due to 
aberrant trafficking of B cells, at least in part as a consequence of lost expression of CXC-
chemokine receptor 4 (Cxcr4), which is a target of FOXO137, 38. Hence, failure to expand 
antigen-specific B cells that have undergone selection in the germinal centre light zone is an 
additional cause of impaired high affinity class-switched antibody production.
Together, these findings contrast the effects of impaired PI3K signalling versus unrestrained 
PI3K signalling in B cells: PI3Kδ deficiency in mature B cells impairs TI antibody 
responses but does not affect CSR or SHM27, whereas, hyperactivation of PI3K signalling 
in mature B cells interferes with CSR and SHM and promotes the expansion of antigen-
specific B cell populations in the germinal centre dark zones (Fig 2) 26, 34, 35.
PI3Kδ is required for mouse CD4+ T cell differentiation and Treg cell function
If PI3Kδ-deficient B cells can undergo CSR, then why do PI3Kδ-deficient mice fail to 
respond to T cell-dependent vaccines? The answer relates to the provision of T cell help for 
B cell development and immunoglobulin class switching. ICOS is a T cell costimulatory 
receptor and a potent activator of PI3Kδ. Mutant mice in which ICOS has been uncoupled 
from PI3Kδ lack follicular helper T (Tfh) cells 39. Similarly, deletion of the p110δ subunit 
in T cells interferes with the development of Tfh cells, leading to a dramatic attenuation of T 
cell-dependent immune responses, including the induction of CSR and SHM in B cells27. 
These results highlight a dual role for PI3Kδ in antibody production: inactivation of PI3Kδ 
in B cells, which leads to activation of FOXO transcription factors, is a prerequisite for CSR 
and SHM26, 34, 35, whereas the activation of PI3Kδ in Tfh cells is a prerequisite for the 
provision of help to supports CSR and SHM in B cells27.
Naïve CD4+ T cell differentiation towards the Th1, Th2 and Th17 cell lineages is delayed or 
attenuated when PI3Kδ is inhibited40–42. This may reflect a key role for FOXO 
transcription factors in the suppression of Th cell differentiation, for example by suppressing 
the Ifng gene43, as well as the requirement for mTOR activity to promote Th cell 
differentiation44. A reduction in Th2 cell responses underpins the resistance of PI3Kδ-
deficient mice to experimentally induced asthma, despite elevated IgE levels25, 45. In 
addition, reduced Th17 cell responses may protect PI3Kδ-deficient mice from experimental 
autoimmune encephalomyelitis, a mouse model of multiple sclerosis46. Although PI3Kδ-
deficient mice only develop a partial Th1 cell response to Leishmania major infections, 
PI3Kδ-deficient mice control Leishmania major infections more effectively than wild-type 
mice, likely due to defects in a regulatory immune cell population47.
PI3Kδ is required for FOXP3+ regulatory T (Treg) cell homeostasis and function48. PI3Kδ-
deficient mice develop colitis because of inappropriate activation of effector T cells by gut 
microbes, and PI3Kδ-deficient Treg fail to suppress experimental colitis22, 48. Patients 
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taking the PI3Kδ inhibitor idelalisib (Zydelig; Gilead) also develop colitis, probably in part 
as a result of reduced Treg cell function49, 50. However, PI3Kδ-deficent mice and mice 
lacking p110δ only in Treg cells mount a more effective immune response against a broad 
range of tumours than wild-type mice51. As with antibody production, these data highlight 
the dual nature of PI3Kδ, which is required both for optimal cytokine production by effector 
T cells and for effective Treg cell-mediated tolerance. Whether PI3Kδ inhibition results in 
impaired or enhanced cell-mediated immune responses is context dependent and therefore 
difficult to predict (Fig 3). Interestingly, inactivation of PI3Kδ results in the 
hyperresponsiveness of dendritic cells and macrophages to Toll-like receptor ligands, 
resulting in increased IL-12 production, which may further contribute to increased cell-
mediated immune responses upon LOF of PI3Kδ 52.
PI3Kδ regulates mouse CD8+ T cell effector functions
PI3Kδ-deficient CD8+ T cells stimulated in vitro are characterised by a reduced abundance 
of mRNAs encoding proteins associated with inflammation and cytotoxicity, such as IFNγ, 
granzyme B and perforin51, 53, 54. By contrast, the expression of genes regulating the 
homing of T cells to the lymph nodes, such as Sell (which encodes CD62L), Ccr7 and Klf2 
are increased in PI3Kδ-deficient CD8+ T cells stimulated in vitro55. Thus, PI3Kδ can 
regulate the homeostatic trafficking of T cells to the lymph nodes and contributes to the 
reprogramming of CD8+ T cells to acquire full effector functions and migrate to peripheral 
tissues.
PI3Kδ is required to reach the optimal magnitude of CD8+ T cell responses in vivo53, 56. 
Nevertheless, PI3Kδ-deficient CD8+ T cells can become fully differentiated cytotoxic T 
cells that produce IFNγ and GZMB required for the killing of virus-infected cells or 
tumours; this suggests that the transcriptional defects described in vitro can, at least in part, 
be overcome by strong inflammatory stimuli in vivo51, 53. Moreover, long-term CD8+ T 
cell memory responses are intact in PI3Kδ-deficient mice53. This is partially because the 
generation of CD8+ effector T cells is reduced during recall responses, whereas the 
generation of long-term memory CD8+ T cells in the lymph nodes and bone marrow is 
preserved53. Similarly, the inhibition of the downstream kinase mTOR with low-dose 
rapamycin during vaccination or infection augments the generation of memory CD8+ T cells 
at the expense of effector CD8+ T cells57. Hence, by promoting mTOR activity, PI3Kδ 
skews CD8+ T cell differentiation in favour of effector T cells, but antagonises the 
generation of memory CD8+ T cells. Thus, strong PI3Kδ activity is associated with effector 
CD8+ T cell differentiation, whereas the maintenance of CD8+ T cell memory requires the 
suppression of PI3K signalling (Fig 4).
Consequences of hyperactive PI3K signalling in mouse T cells
Similar to B cells, the consequence of PI3Kδ hyperactivation in mouse T cells can be 
inferred from experiments using PTEN-deficient or FOXO1-deficient T cells. Loss of PTEN 
expression in early T cell development leads to the development of an immature T cell 
lymphoma and a hyperactivated T cell phenotype, characterised by the increased secretion of 
effector T cell cytokines and autoimmunity58. Similar results were observed in mice 
expressing a mutant p85α protein that lacked inhibitory contacts with the p110 catalytic 
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subunit59. Deleting PTEN in mature CD4+ T cells also resulted in enhanced cytokine 
production and Th cell function, but did not induce T cell transformation or autommunity60. 
Furthermore, loss of Foxo1 leads to a loss of memory CD8+ T cell development after 
infection61. Together, these data indicate a unique sensitivity of thymocytes to PI3Kδ-
dependent T cell transformation, and suggest that PI3Kδ signalling also affects central 
tolerance to self-peptides. Overall, these studies suggest that unrestrained PI3K signalling in 
T cells lowers their threshold of activation.
Alterations in PI3Kδ signalling leads to PIDs in humans
Both LOF and GOF mutations in PI3K genes that cause PIDs in humans have been 
described. Our understanding of the underpinning causes of these PIDs has been greatly 
aided by the use of mouse models (as described in the previous section), but have also 
furthered and challenged our understanding of the functions of PI3Kδ (Box 2 and below).
Loss of function of p85α or p110δ in humans
As with mouse T cells, inhibition of PI3Kδ in human T cells suppresses the expression of 
effector cytokines such as IFNγ, IL-4 and IL-17 41. A single patient with a homozygous 
PIK3R1 mutation that generated a premature stop codon (resulting in the loss of p85α and 
markedly decreased expression of p110δ) presented with recurrent pneumonia associated 
with agammaglobulinemia and severe B cell lymphopenia due to a block in early B cell 
development10. The development of colitis in this patient was attributed to antibody-
deficiency and the consequent outgrowth of gut pathogens, but could also be due to Treg cell 
deficiency10. Similarly, one patient lacking p110δ as a result of the inheritance of two 
different non-functional alleles has been described, and this patient presented with 
sinopulmonary infections, septic arthritis, inflammatory bowel disease and autoimmune 
hepatitis, associated with hypogammaglobulinemia9. Loss of p110δ was again associated 
with severe B cell lymphopenia and fewer memory T cells9. Thus, the two reported patients 
with a loss of PI3Kδ suffer infections associated with the lack of B cells. Interestingly, in 
mice, a complete block in B cell development and severe mature B cell lymphopenia are 
only observed when both the p110α and p110δ are inactivated in the B cell lineage24, 
suggesting a redundancy between these isoforms in mice that is not reflected in humans. The 
inflammatory and autoimmune manifestations in PI3Kδ-deficient humans, possibly 
associated with reduced Treg cell function, underscore the importance of PI3Kδ in 
maintaining self-tolerance. PI3Kδ is also required for the generation of ROS by human 
neutrophils and treatment of patients with the PI3Kδ inhibitor idelalisib can lead to 
neutropenia and increased risk of infections 49, 62.
Activating PI3Kδ mutations that underlie human APDS
In 2013, groups in Cambridge (UK) and Bethesda (US) reported whole-exome sequencing 
studies of patients with uncharacterised PID, which revealed causal heterozygous activating 
mutations in PIK3CD1, 2. The UK patients were identified by screening cohorts of PID 
patients with a high frequency of recurrent chest infections and bronchiectasis, features 
suggestive of antibody deficiency, although frequent herpes viral infections and an increased 
proportion of effector T cells were also noted1. The US cohort were identified on the basis 
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of persistent viremia with herpes-family viruses, which are commonly associated with 
altered T cell or natural killer (NK) cell function, in addition to frequent airway infections2. 
Because both B cells and T cells are affected in these patients, APDS should be 
characterised as a combined immunodeficiency1–5.
This immunodeficiency had previously been noted in a Taiwanese boy by targeted 
sequencing of the PIK3CD gene in children with B cell immunodeficiency, although the 
nature of the mutation (GOF or LOF) was not elucidated63. Subsequently, a number of 
additional studies have identified APDS patients with mutations in PIK3CD5, 7, 64–69 or 
PIK3R16, 70–73. Patients with GOF mutations in either of these genes appear to largely 
phenocopy each other, despite the fact that p85α is ubiquitously expressed and can pair with 
p110α and p110β in addition to p110δ. There is some evidence for effects of the PIK3R1 
mutation outside the immune system (for example, short stature, Box 1)74, but detailed 
analyses of the effects of this p85α defect on p110α or p110β have not yet been reported. 
The biochemical and clinical symptoms of patients with APDS1 (PIK3CD mutations) or 
APDS2 (PIK3R1 mutations) are similar, suggesting that the pathological features of both 
syndromes are a consequence of aberrant and hyperactive PI3Kδ signalling1–4. Here we use 
the generic term APDS unless referring specifically to either. A milder form of APDS-like 
immunodeficiency has been described in Cowden disease, caused by heterozygous loss of 
PTEN, although the increases in PIP3 and pAKT levels from these patient T cells was less 
obvious than observed in the T cells from patients with APDS69, 75.
The most frequent mutation in PIK3CD (c.3061G>A; OMIM 602839 http://www.omim.org/
entry/602839#0001) encodes a glutamic acid for lysine substitution at position 1021 
(E1021K) of p110δ (Table 1). To date, this mutation has only been found in APDS patients 
and their affected family members but not among healthy unrelated subjects1. Patients with 
the E1021K mutation have been found across continents and ethnicities. Genetic analysis 
showed no founder effect, demonstrating that E1021K is a recurrent mutation that appeared 
de novo independently in multiple unrelated families1.
p110δ with the E1021K mutation has increased lipid kinase activity, as shown using 
recombinant proteins in vitro and by measuring PIP3 and AKT phosphorylation levels in 
patient-derived T cells1, 2. The E1021K mutation is located in the C-terminal lobe of the 
kinase domain of p110δ, similarly to the oncogenic H1047R mutation of p110α, and 
enhances the membrane association of p110δ in vitro, facilitating more effective 
phosphorylation of its lipid substrate PtdIns(4,5)P2; this increases accumulation of PIP3 and 
lowers the activation threshold of PI3Kδ1, 17 (Fig 3). Other missense p110δ mutations — 
N334K, C416R and E525K — have also been shown to cause APDS, although they are less 
frequent than E1021K2 (Table 1). Interestingly, GOF mutations of the homologous amino 
acid residues of p110α (N345, C420 and E545, respectively), have been identified in tumors 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) and are thought to interfere with the 
inhibitory contacts imposed by p85α and hence increase the lipid kinase activity of the p110 
subunit17; this implies that a similar mechanism may lead to enhanced PIP3 accumulation in 
cells from patients with APDS with the equivalent mutations and hence the immune 
modulation seen in APDS (Fig 4). APDS is thus distinct from most other PIDs in that it is 
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the hyperactivation of signaling pathways, rather than their inhibition, that leads to immune 
dysfunction. This distinction offers unique therapeutic opportunities (see below).
A heterozygous splice site mutation before exon 11 of the PIK3R1 gene leads to an in-frame 
fusion of exon 10 with exon 12, resulting in the deletion of 42 amino acids in p85α (del p.
434 – 475, OMIM: http://omim.org/entry/616005) p55α and p50α3, 4(Fig 3). These amino 
acids lie in the inter-SH2 domain that regulates the activity of the catalytic p110 subunits76. 
Oncogenic mutations in this region result in mutant proteins that can bind p110 subunits but 
are less effective at inhibiting their enzymatic activity76, 77. Similar to mutations in the 
p110δ subunit, this is thought to lower the threshold of activation for PI3Kδ. The mutant 
p85αdel434–475 protein (Fig 4, ΔEx11) was shown to stabilize p110δ, which was expressed at 
near normal levels in patient cells, but its inhibitory function was impaired, leading to 
increased PI3Kδ activity3, 4. Because the net effect of the p85α (del p.434 – 475) is 
increased PI3Kδ activity, we consider it as a GOF mutation, even though it is strictly 
speaking a mutation resultin in loss of inhibitory function.
Thus, a number of different mutations in PIK3R1 or PIK3CD lead to increased activity of 
PI3Kδ, either by disrupting inhibitory contacts between p85α and p110δ or by increasing 
the affinity of p110δ for the plasma membrane, promoting its interaction with the lipid 
substrate and hence facilitating phosphorylation of PtdIns(4,5)P2.
Activating PI3Kδ mutations lead to impaired B cell function and vaccine responses
Immunoglobulin levels in patients with APDS are variable, ranging from isolated specific 
antibody deficiency or IgG subclass deficiency to severe hypogammaglobulinemia, often 
with increased IgM levels. In one cohort, 10% of a heterogeneous PID cohort who suffered 
recurrent infections were found to have APDS1, whereas in a second cohort of mainly 
antibody-deficient PID patients, fewer than 1% had PIK3CD mutations5.
Most APDS patients have increased proportions of circulating transitional B cells , reduced 
class-switched memory B cells, and impaired vaccine responses1,3. In vitro, APDS patient-
derived B cells showed impaired CSR (consistent with the observed tendency for these 
patients to have reduced IgG and increased IgM levels), but in contrast to the findings in 
mouse cells, this was not associated with reduced AICDA mRNA levels2. As noted above, it 
is possible that PI3K regulates AID function by post-transcriptional mechanisms as well as 
by regulation of mRNA expression35. Alternatively, the defective CSR in APDS patients 
could be due to defects in germinal centre Tfh cells78, aberrant B cell maturation and/or 
defective migration of B cells during the germinal centre reaction in the spleen, as shown for 
FOXO1-deficient B cells in mice37, 38. The basis for the increased percentage of circulating 
transitional B cells in patients with APDS remains incompletely understood, but is likely to 
be a consequence of impaired B cell maturation and/or an increased propensity for mature B 
cells to undergo apoptosis1. These findings are in marked contrast to the dramatic loss of B 
cells and agammaglobulinemia seen in the rare patients with LOF mutations in PIK3R1 or 
PIK3CD.
Encapsulated bacteria (Haemophilus influenzae and Streptococcus pneumoniae) are the 
most frequent respiratory isolates from patients with APDS (Box 1), which is consistent 
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with a substantial defect in antibody-mediated immunity. However, the severity of 
respiratory infections and resulting structural damage in the lungs do not correlate well with 
the reduction in B cell numbers or the extent of immunoglobulin deficiency6, 7, and 
immunoglobulin replacement therapy alone does not appear to limit the progress of lung 
damage in patients with APDS 6, 7. One explanation for this apparent discrepancy is that 
PI3Kδ hyperactivation causes additional defects (such as altered T cell functions or innate 
immune cell dysfunction) that also contribute to an increased susceptibility to respiratory 
bacterial infections. As mentioned above, PI3Kδ has been shown to promote ROS 
production by human neutrophils, which could cause collateral damage if excessively 
produced during infections62. However, analysis of APDS patient neutrophils did not reveal 
an obvious increase in ROS production, or indeed in PIP3 production, in response to 
stimulation with microbial peptides1. However, the increased susceptibility of patients with 
APDS to staphylococcal skin infections and abscess formation1, 65, as well as defective 
killing of mycobacteria by macrophages from an APDS patient64, suggest that 
abnormalities may indeed exist in the innate immune system which remain to be more 
completely investigated. Increased PI3K activity has been shown to compromise the 
migratory accuracy of neutrophils, and hence prolong their tissue-transit time, leading to 
increased opportunities for bystander tissue injury mediated by surface-associated neutrophil 
proteases79. Hence a wide range of impaired immune cell functions, affecting both innate 
and adaptive immune responses, may contribute to recurrent infection and bronchiectasis in 
patients with APDS.
Activating PI3Kδ mutations cause T cell senescence
Peripheral blood analysis revealed an increase in effector-type T cells with a severe 
reduction in naïve T cell numbers1–4. Freshly isolated peripheral blood cells demonstrated 
reduced secretion of cytokines and increased apoptosis upon TCR restimulation1–3. 
Unexpectedly, acute PI3Kδ inhibition in T cells from APDS patients reduced TCR-triggered 
apoptosis, suggesting a previously unappreciated role for PI3Kδ signalling in pro-apoptotic 
pathways1, 3. However, T cell blasts that had escaped apoptosis and expanded after 
activation in vitro showed increased production of IFNγ, TNF and granzyme B2. Thus, 
chronic hyperactivation of PI3Kδ signalling promotes T cell differentiation into terminal 
effector cells with increased sensitivity to TCR-induced cell death and dysregulation of 
cytokine secretion.
Notably, the expression of CD57, which is a marker of senescence on CD8+ T cells 80, was 
consistently high on patient cells2, 4. Subsequent analyses confirmed shortening of telomere 
length in APDS patient lymphocytes4, suggesting T cell senescence contributes to immune 
dysfunction in APDS patients. Patients free from viraemia also presented with increased 
numbers of CD57+CD8+ T cells2; therefore, CD8+ T cell senescence in APDS is likely to be 
distinct from T cell exhaustion driven by chronic viral infections. T cell senescence due to 
telomere shortening results in cell cycle arrest while maintaining most other responses to 
antigen81, whereas T cell exhaustion from chronic antigen stimulation results in the 
upregulation of co-inhibitory receptors that broadly dampen TCR signalling and antigen 
responsiveness82. These findings point to in vivo hyperproliferation (which is consistent 
with enlarged spleen and lymph nodes) as the underlying cause of the T cell senescence and 
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short telomeres in APDS patients and support the connection between cell division and 
effector T cell differentiation.
T cells from APDS patients exhibit increased activity of mTOR2, a key mediator of the 
switch from a catabolic naïve state to an anabolic effector state during a T cell response83. 
Increased glucose uptake is also observed in T cells from APDS patients compared with 
healthy subjects2, 4. These findings indicate that changes in T cell metabolism induced by 
hyperactive PI3Kδ signalling may underlie the hyperproliferation associated with T cell 
senescence in APDS patients. Further studies will be needed to determine if elevated mTOR 
activity is a direct consequence of increased PI3Kδ activity or whether it also reflects the 
skewed effector phenotype of T cells in APDS patients. PI3Kδ inhibition reduced, but did 
not ablate, phosphorylation of S6K (a component of the mTOR signalling pathway) in 
APDS T cells, confirming that PI3Kδ contributes to mTOR activity in these cells4. 
Therefore, unrestrained and prolonged PI3Kδ and mTOR activity may drive APDS T cells 
towards senescence rather than allowing T cells to revert to a metabolically quiescent 
phenotype after antigen exposure (Fig 3).
The main clinical manifestation of abnormal T cell function in APDS is herpes viral 
infection. All of the patients with PIK3CD mutations that were described by Lucas et al.3 
experienced chronic Epstein–Barr virus (EBV) and/or cytomegalovirus (CMV) viremia; in 
other studies the occurrence of CMV/EBV was lower1, 4–7, although herpes simplex virus 
and varicella zoster virus infections were also noted. These inter-study differences may 
reflect the case-finding strategies, immune profiles and/or pathogen exposure of the patients. 
Surprisingly, given the abnormal T cell profiles, few other opportunistic infections have been 
reported. Some cases of problematic viral warts and molluscum contagiosum have been 
identified7, perhaps suggesting impaired NK cell function, though this has yet to be 
confirmed experimentally.
Treatment options for patients with APDS
As APDS patients often present with reduced IgG levels or respond poorly to vaccines, 
many are treated with immunoglobulin replacement therapy that is often supplemented with 
prophylactic antibiotics. While this may have been effective in some patients, it has not 
prevented the acquisition or progression of bronchiectasis in others, even when the treatment 
was initiated in childhood6, 7. Haematopoietic stem cell transplantation (HSCT) is a 
treatment option, particularly for younger patients. HSCT could also help prevent or treat 
malignant B cell transformation, which occurs in 10–15% of patients. Several patients have 
undergone HSCT and, although significant improvements have been noted6, 7, the follow up 
of these patients is too short to make a definitive conclusion.
Rapamycin
Lucas and colleagues reported use of the mTOR inhibitor rapamycin in one patient, who 
showed a dramatic reduction in lymphadenopathy and hepatosplenomegaly and 
improvement in T cell subset defects2. Similar improvements have been noted in a recent 
case report of a four year old boy also treated with rapamycin68. However, the effect of 
rapamycin on B cell homeostasis and humoral immune responses in APDS patients remains 
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to be determined. It is important to keep in mind that PI3Kδ regulates other pathways in 
addition mTOR, and conversely, that mTOR is also regulated byPI3K-independent 
pathways8. Moreover, mTOR regulates the expression of PTEN such that treatment of T 
cells with rapamycin can actually increase PI3K signalling in T cells84, potentially 
exacerbating aspects of hyperactive PI3Kδ signalling in APDS.
PI3Kδ inhibitors
The PI3Kδ inhibitor idelalisib is licenced for use in chronic lymphocytic leukaemia and non-
Hodgkin lymphoma85, 86. However, idelalisib has a considerable side-effect profile, 
including pneumonitis, pneumonia, transaminitis and colitis in up to 42% of patients 
treated49. Histologically, the colitis in these patients is reminiscent of that seen in mice 
lacking functional PI3Kδ, suggesting it is an on-target effect rather than a compound-
specific effect49. It is possible that APDS patients will benefit from lower doses of PI3Kδ 
inhibitors, which are effective for the treatment of B cell lymphomas, and hence may be 
spared some of the more severe side effects. Another possibility is that topical 
administration of the PI3Kδ inhibitor may avoid some of the adverse effects.
Two clinical trials of PI3Kδ inhibitors in patients with APDS have recently been announced: 
NCT02435173 sponsored by Novartis for an oral PI3Kδ inhibitor and NCT02593539 
sponsored by GlaxoSmithKline for an inhaled PI3Kδ inhibitor. To correct systemic immune 
defects, including lymphoproliferation and lymphoma, an oral inhibitor is more likely to be 
effective; however, an inhaled inhibitor is expected to have a better safety profile and may be 
appropriate for patients who are primarily affected by airway infections and potentially may 
limit progression of bronchiectasis.
Conclusions
GOF mutations in PI3Kδ lead to a range of B and T cell developmental and functional 
defects that compromise host defence, leading to recurrent bacterial and viral infections 
(Box 1). This distinguishes APDS patients from patients with LOF of PI3Kδ who present 
with much more severe B cell lymphopenia and agammaglobulinemia, but not T cell 
senescence. In general, GOF mutations are unusual causes of immune deficiency87. The 
therapeutic options for LOF of PI3Kδ may be limited to immunoglobulin replacement 
therapy, bone marrow transplants and perhaps gene therapy. Although these are also options 
for APDS, existing (mTOR inhibitors) and emerging (PI3Kδ inhibitors) therapeutics offer 
the additional possibility of correcting the biochemical defects that arise from APDS-
associated mutations, and the impact of these agents is currently being explored.
The fact that both LOF and GOF PI3Kδ mutations lead to immunodeficiencies highlights 
the concept that this pathway must be precisely and dynamically modulated for optimal 
immune cell function: too much, too little or the inability to turn the pathway on or off as 
needed, has detrimental consequences (Fig 3) 8. These considerations raise the possibility 
that aberrant PI3K signalling in immune cells may also occur in non-genetic diseases or 
conditions that lead to increased susceptibility to infections.
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Many fundamental questions remain to be answered. How common is APDS among PID 
patients? What are some of the genetic or environmental influences that lead to the clinical 
heterogeneity of APDS patients? Are there mutations in other genes that lead to 
hyperactivation of PI3Kδ and APDS-like syndromes? Why do APDS T cells undergo 
apoptosis when stimulated? Why does recurrent airway infection lead to bronchiectasis more 
frequently in APDS patients than in other PIDs? Can PI3Kδ inhibitors restore normal 
immune function in APDS? The answers to these and further questions will require more 
detailed analysis of APDS patient cohorts, genetic screening of larger PID cohorts, and 
establishment of mouse models that mimic this intriguing new disease and help evaluate 
different therapeutic strategies.
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Glossary terms
Activated PI3Kδ syndrome (APDS)
The term APDS encompases two syndromes: APDS1 (also known as PASLI-CD), which 
result from a mutation in the PIK3CD gene that lead to the hyperactivation of the p110δ 
subunit of PI3Kδ; and.APDS2 (also known as PASLI-R1), which results from splice 
mutations in PIK3R1 that lead to exon skipping and produces a truncated p85α protein with 
reduced inhibition of p110δ.
Activation-induced cytidine deaminase (AID)
An enzyme that is required for two crucial events in the germinal centre: somatic 
hypermutation and class-switch recombination.
Germinal centre reaction
Germinal centres are specialised structures within spleens and lymph nodes where B cells 
present antigen to T cells and in return, are selected to undergo CSR and SHM.
Hypogammaglobulinemia
An immune disorder characterised by low serum IgG levels.
Immune complexes
Complexes of antigen bound to antibody and, sometimes, components of the complement 
system. The levels of immune complexes are increased in many autoimmune disorders, in 
which they become deposited in tissues and cause tissue damage.
Class-switch recombination (CSR)
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The process by which proliferating B cells rearrange their DNA to switch from expressing 
IgM (or another class of immunoglobulin) to expressing a different immunoglobulin heavy-
chain constant region, thereby producing antibody with different effector functions.
T cell-independent (TI) antibody response
An antibody response to polymeric antigens, such as polysaccharides and lipids, that does 
not require T cell help.
Primary immunodeficiency (PID)
An inherited disorder of the immune system that leads to recurrent infections and/or immune 
dysregulation. Currently there are around 84,000 patients diagnosed worldwide with PID.
Somatic hypermutation (SHM)
A unique mutation mechanism that is targeted to the variable regions of rearranged 
immunoglobulin gene segments. Combined with selection for B cells that produce high-
affinity antibody, SHM leads to affinity maturation of B cells in germinal centres.
T follicular helper cells (Tfh cells)
CD4+ T helper cells that are essential for the induction of class switching in the germinal 
centres of secondary follicles during antibody responses to T cell-dependent antigens.
Transitional B cells
Immature B cells that have left the bone marrow for the spleen and are precursors of 
follicular B cells, marginal zone B cells and B1 B cells.
Senescence
A state in which a cell fails to progress through the cell cycle due to activation of the DNA 
damage response, which can occur upon extreme shortening of telomeres.
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Box 1
Clinical features of APDS
Patients with APDS display features of both immune deficiency and of immune 
dysregulation:
• Recurrent lung, ear and sinus infections (with encapsulated bacteria such as 
Haemophilus influenzae and Streptococcus pneumoniae, which require 
opsonisation for effective killing) are near-universal and are associated with a 
high incidence of organ damage including hearing impairment and 
bronchiectasis (permanent airway scaring)1–4.
• Severe, recurrent or persistent infections with herpes family viruses are 
common, in particular chronic EBV or CMV viremia, and HSV and VZV 
infections1, 3–7. Frequent isolates of some respiratory viruses such as 
adenovirus and echovirus have also been described 1.
• Opportunistic infections are rare, although a few patients have experienced 
recurrent viral warts or molluscum contagiosum infections49.
• An increased incidence of abscess formation, lymphadenitis and cellulitis 
with gram-positive bacteria (mainly Staphylococcus aureus), and defective 
killing of mycobacteria by macrophages isolated from a patient with APDS 
suggest a mild deficit in innate immunity1, 64.
• Benign lymphoproliferation (lymphadenopathy, hepatosplenomegaly and 
focal nodular lymphoid hyperplasia) is a common feature of all patients with 
APDS that have been studied to date.
• Histopathological analysis of lymphoid tissue from affected patients 
demonstrates atypical follicular hyperplasia with attenuation of mantle zones 
in APDS1, and small B cell follicles in APDS2. Germinal centres were 
disrupted by infiltrating T cells (often PD1-positive) in both APDS1 and 
APDS2 6, 7.
• There is a high frequency of lymphoma associated with APDS, encompassing 
a wide range of histopathological patterns1, 2, 7, 65, 67.
• Immune cytopenias (thrombocytopenia, haemolytic anaemia and neutropenia) 
and autoimmune-like solid organ conditions (such as juvenile arthritis, 
glomerulonephritis, thyroiditis and sclerosing cholangitis) have also been 
reported7, 66, with a frequency of 34% in a cohort of 53 patients with APDS1 
7 and 17% in a cohort of 36 patients with APDS2 6.
• Mild developmental delays has been observed in both APDS1 and APDS2 
cohorts, with a higher incidence in APDS2 (31% versus 19%) 6, 7.
• Growth retardation is common in patients with APDS2 6, 73, 74 but does not 
seem to be a feature of APDS1 and may relate to the association of 
heterozygous mutations in PIK3R1 with SHORT syndrome (short stature, 
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hyperextensibility of joints, hernia, ocular depression, Rieger anomaly and 
teething delay)88–91.
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Box 2
Lessons learned from APDS
Although the normal physiological role of PI3Kδ has been extensively studied in mouse 
models, investigation of patients with APDS has provided important new insights about 
the biology of this kinase in humans.
• Mutations causing LOF or GOF of PI3Kδ lead to immunodeficiency. This 
illustrates how this pathway needs to be dynamically regulated for normal 
immune cell function.
• The previously reported roles for PI3Kδ in B cell function and humoral 
immunity did not predict the increase of transitional B cell numbers that have 
been observed in APDS patients.
• Defects in CSR that are not attributable to defective AICDA mRNA 
expression (encoding AID) remain to be fully understood.
• Augmented PI3Kδ results in a loss of naïve T cells and an in vivo 
proliferative burst that causes lymphoproliferative disease and drives the T 
cells toward cellular senescence (a phenotype that is poorly mimicked in 
mouse models due to long telomeres).
• Moreover, patient T cells are highly susceptible to TCR restimulation-induced 
cell death, indicating a previously unappreciated role for PI3Kδ in a pro-
apoptotic signalling pathway.
• The high proportion of patients with severe respiratory infections and 
bronchiectasis suggests a role for PI3Kδ in promoting inflammation of the 
lungs by mechanisms that are incompletely understood, but which may 
indicate a key role for PI3Kδ in airway-associated innate immune responses, 
in addition to its role in humoral immunity.
• Previously, LOF point mutations in PIK3R1 were shown to cause SHORT 
syndrome 88–91. It is unclear why the ΔEx11 mutations that cause APDS2 
manifest primarily as PID; however, it is of interest to note at least one case 
where this mutation was suggested to relate to SHORT syndrome 73. This 
indicates that PIK3R1 ΔEx11 may have distinct effects on different p110 
isoforms in different tissues.
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• PI3Kδ is a key signal transduction node in cells of the immune system. This 
kinase complex is acutely activated in B cells and T cells after exposure to 
antigen and controls many aspects of lymphocyte development and 
differentiation, in part via the AKT, FOXO1 and mTOR pathways.
• Rare loss-of-function mutations in PI3Kδ also cause immunodeficiency and 
immune-mediated pathologies, including colitis. The PI3Kδ inhibitor 
idelalisib causes frequent colitis at doses tested in leukaemia/lymphoma trials, 
possibly due to effects on Treg.
• Activated PI3Kδ Syndrome (APDS) is a newly described primary 
immunodeficiency caused by hyperactive PI3Kδ signalling and resultant T 
cell senescence/death and impaired antibody responses. APDS is generally 
characterized by recurrent sinopulmonary infections with structural lung 
damage, viremia with herpes family viruses, lymphoproliferative disease, and 
increased risk of B cell malignancies.
• APDS1 patients have a heterozygous mutation in PIK3CD, the gene encoding 
the p110δ catalytic subunit of PI3Kδ, whereas APDS2 patients have a 
heterozygous mutation in PIK3R1, the gene encoding the p85α regulatory 
subunit of PI3Kδ. Both sets of mutations lead to higher intrinsic activity of 
PI3Kδ.
• To date, most APDS patients have been treated with antibody replacement 
therapies and some with the mTOR inhibitor rapamycin. In the future, PI3Kδ 
inhibitors may be used to treat APDS patients, possibly as the first example of 
targeted therapy against a hyperactive mutant kinase in primary 
immunodeficiency.
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Figure 1. BCR signaling
PI3Kδ is a heterodimeric enzyme, typically composed of a p85α regulatory subunit and a 
p110δ catalytic subunit. In B cells, PI3Kδ is activated upon cross-linking of the BCR, after 
stimulation with IL-4 or by the chemokine CXCL13 via CXCR5. The BCR co-opts the co-
receptor CD19 or the adapter protein BCAP, both of which have YXXM motifs to which the 
p85α SH2 domains can bind. The IL-4R co-opts IRS1, which also has YXXM motifs. The 
mechanism whereby CXCR5 is coupled to PI3Kδ remains to be defined (indicated by a 
dotted line). PI3Kδ signalling through AKT promotes the activation of mTOR and 
suppresses FOXO1 function (via phosphorylation-dependent nuclear export). FOXO1 is a 
transcription factor that activates the genes encoding RAG proteins involved in V(D)J 
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recombination, IKAROS which is required for early B cell development, CD62L which is 
required for homing to lymph nodes and AID, which is required for CSR and SHM. The 
amino acid sensor mTOR contributes to the growth and proliferation of B cells. All proteins 
coloured in green have been affected by LOF mutations causing PID. Of these, only p85α 
and p110δ have also been affected by GOF mutations causing APDS.
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Figure 2. TCR signaling
PI3Kδ is a heterodimeric enzyme, typically composed of a p85α regulatory subunit and a 
p110δ catalytic subunit. In T cells, the TCR, the costimulatory receptor ICOS and the IL-2R 
can activate PI3Kδ. ICOS contains a YXXM motif in the cytoplasmic domain which is 
essential for ICOS-mediated co-stimulation. Precisely how the TCR activates PI3Kδ remains 
incompletely understood, though TCR ligation is known to induce ZAP70-mediated 
phosphorylation of LAT. Whether PI3K binds LAT directly or via other adapter proteins 
remains to be established. Mechanisms of PI3Kδ activation downstream of IL-2R are even 
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less clear, but a role for JAK3 has been implicated. PI3Kδ contributes to the downregulation 
of the expression of IL-7Rα and CD62L,via the AKT-dependent inactivation and nuclear 
export of FOXO1, preparing the T cell to exit the lymph nodes and circulate through the 
vascular systems and organs. PI3Kδ also increases metabolism and contributes to T cell 
effector-associated phenotypes by promoting activation of mTOR.
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Figure 3. Dynamic regulation of PI3Kδ signaling in the immune system
PI3Kδ activity needs to be dynamically regulated for normal immune cell function, as some 
cell types and processes require high PI3Kδ activity, while other depend on low PI3Kδ 
activity (e.g., if they require FOXO1-dependent gene transcription). Problems arise if cells 
cannot increase or suppress PI3Kδ due to mutations, and have chronically low or high 
PI3Kδ activity. Immunosuppression is associated with loss-of function and gain-of-function 
in PIK3CD, which encoded the PI3Kδ subunit p110δ. Illustrated are some key cell types and 
processes affected by high or low PI3Kδ activity, and the consequences of being locked in 
one state or the other.
In the healthy state (top), PI3Kδ signalling is low in naïve and memory T cells, which are 
characterised by low mTOR and metabolic activity and high expression of FOXO1-
dependent lymph node homing receptors. In activated effector T cells, PI3Kδ activity is high 
as a consequence of TCR, IL2R and ICOS signalling. Effector T cells are also characterised 
by high mTOR and metabolic activity, whereas FOXO1-dependent expression of lymph 
node homing receptors is reduced.
Inhibition of PI3K signalling during thymic development is thought to favour the 
development of Treg. However, PI3Kδ activity is required to maintain normal numbers of 
Treg cells in the peripheral lymphoid tissues and for Treg to adopt an effector phenotype, 
especially peripheral tissues.
Maintainenance of low-level signaling (also referred to as tonic signalling) via PI3Kδ (and 
to a lesser extent PI3Kα) maintains survival of naïve follicular B cells. Upon activation, 
PI3K is increased and this contributes to B cell proliferation. However, for B cells to 
undergo CSR in the GC, PI3Kδ signalling needs to be tuned back down to allow higher 
FOXO1 transcription and proper AID targeting.
In disease states (bottom) caused by gain-of-function or loss-of-function in PI3Kδ, the 
proper dynamics of signalling result in cellular defects associated with immunodeficiency. 
Chronically high PI3Kδ activity leads to T cell (more senescence, death, and Tregs) and B 
cell (more transitional B cells and less CSR and SHM) abnormalities with increased 
susceptibility to B cell lymphoma, infections, and lymphoproliferative disease. Chronically 
low PI3Kδ activity leads to a different set of T cell (poor responses and low Tregs) and B 
cell (low numbers) abnormalities resulting in prevalent infections and colitis.
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Figure 4. APDS mutations lower the threshold of PI3Kδ activation
a | Schematic diagram of the protein domains in the p85α regulatory and p110δ catalytic 
subunits with mapped interactions shown with lines, where the black line indicates the 
binding interaction mediated constitutive interaction and the red lines indicate inhibitory 
contacts. The locations of the described amino acid substitutions caused by APDS mutations 
are indicated. ABD: adaptor-binding domain, RBD: RAS-binding domain, SH3: SRC-
homology 3 domain, P: proline-rich region, BH: breakpoint-cluster region homology 
domain, SH2: SRC-homology 2 domain, N-: N-terminal, C-: C-terminal, i-: inter-.
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b | Class IA PI3Ks are activated by their recruitment to tyrosine kinase-associated receptors 
at the plasma membrane. The p85α regulatory subunit (p50 fragment containing the N-
SH2–i-SH2–C-SH2 domains, shown here in blue) stabilizes the p110δ catalytic subunit 
(orange) through constitutive binding of the p85α i-SH2 domain (coiled portion) to the 
p110δ adaptor-binding domain (ABD). Binding of the p85α SH2 domains to tyrosine-
phosphorylated residues on an activated receptor releases the inhibitory contacts between the 
p85α SH2 domains and the p110δ C2, helical and kinase domains (shown in red in part a). It 
is possible that the ΔEx11 mutation (red) that truncates the p85α inter-SH2 domain affects 
p110δ more than it affects p110α, hence the lack of more dramatic pleiotropic effects on 
growth and metabolism in individuals with this deletion. Ras–GTP further tethers p110δ to 
the membrane by binding to the Ras-binding domain (RBD) of p110δ. GOF mutations in 
PIK3R1 and PIK3CD increase kinase activity by interfering with inhibitory interactions 
between the p85α regulatory and p110δ catalytic subunit (ΔEx11, N334K, C416R and 
E525K), or by increasing the affinity of p110δ for the plasma membrane (E1021K). The 
E1021K mutations may also interfere with inhibitory contacts from the p85α C-SH2 
domain1. See ref (17) and references therein for further details of the structures and 
mechanisms of regulation of PI3Kδ.
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Table 1
PI3K subunits and APDS mutations
PI3K class Gene Protein Expression Selected functions APDS-associated mutations**
Catalytic subunits
Class IA PIK3CA p110α Ubiquitous • Metabolism
• Angiogenesis
ND
PIK3CB p110β Ubiquitous • Metabolism
• Neutrophil activation
ND
PIK3CD p110δ Haematopoietic cells 
and CNS
• Immunity
Class IB PIK3CG p110γ Haematopoietic cells 
and heart
• Immunity
• Metabolism
• Cardiac
N334K (1) 2
C416K (2) 65
E525K (7) 2, E525A (3)69
E1021K (63) 1, 2, 5, 7, 63–69
Regulatory subunits
Class IA PIK3R1 p85α, p55α, p50α Ubiquitous • Metabolism
• Immunity
del p.434-475 (43) 3, 4, 6, 70–
74
PIK3R2 p85β Ubiquitous • Metabolism
• Immunity
ND
PIK3R3 p55γ Brain and testes • Unknown ND
Class IB PIK3R5 p101 Haematopoietic cells • Immunity ND
PIK3R6 p84* Haematopoietic cells • Immunity ND
*Also known as p87.
**Number of cases reported in brackets. ND, none described
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